LGND vs. HALO, MDGL, IONS, ALKS, FOLD, GERN, MNKD, BCRX, DVAX, and CLDX
Should you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Amicus Therapeutics (FOLD), Geron (GERN), MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Dynavax Technologies (DVAX), and Celldex Therapeutics (CLDX). These companies are all part of the "biotechnology" industry.
Ligand Pharmaceuticals vs.
Ligand Pharmaceuticals (NASDAQ:LGND) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, risk, earnings, media sentiment, dividends and valuation.
In the previous week, Halozyme Therapeutics had 7 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 10 mentions for Halozyme Therapeutics and 3 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.41 beat Halozyme Therapeutics' score of 1.31 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.
91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are held by institutional investors. 5.9% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Ligand Pharmaceuticals has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.
Ligand Pharmaceuticals presently has a consensus price target of $147.00, suggesting a potential upside of 26.13%. Halozyme Therapeutics has a consensus price target of $60.89, suggesting a potential upside of 7.50%. Given Ligand Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Ligand Pharmaceuticals is more favorable than Halozyme Therapeutics.
Halozyme Therapeutics has higher revenue and earnings than Ligand Pharmaceuticals. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Ligand Pharmaceuticals received 28 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. Likewise, 70.77% of users gave Ligand Pharmaceuticals an outperform vote while only 69.40% of users gave Halozyme Therapeutics an outperform vote.
Halozyme Therapeutics has a net margin of 41.43% compared to Ligand Pharmaceuticals' net margin of 29.68%. Halozyme Therapeutics' return on equity of 179.82% beat Ligand Pharmaceuticals' return on equity.
Summary
Halozyme Therapeutics beats Ligand Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Ligand Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ligand Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:LGND) was last updated on 2/1/2025 by MarketBeat.com Staff
